Drs. Elizabeth Yeu and John Berdahl define presbyopia and discuss the impact of presbyopia on a patient’s everyday life. They also discuss the incidence and prevalence of presbyopia in the general population. This is Part 1 of 2.
This activity is supported by an unrestricted educational grant from Orasis Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Elizabeth Yeu, MD
Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Cornea, Cataract, External Disease, and Refractive Surgery
Assistant Professor, Department of Ophthalmology
Eastern Virginia Medical School
Norfolk, VA
John P. Berdahl, MD
Vance Thompson Vision
Associate Professor of Ophthalmology
Sanford School of Medicine
Cataract, Refractive, Glaucoma and Corneal Surgeon
Sioux Falls, South Dakota
Elizabeth Yeu, MD
Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Cornea, Cataract, External Disease, and Refractive Surgery
Assistant Professor, Department of Ophthalmology
Eastern Virginia Medical School
Norfolk, VA
John P. Berdahl, MD
Vance Thompson Vision
Associate Professor of Ophthalmology
Sanford School of Medicine
Cataract, Refractive, Glaucoma and Corneal Surgeon
Sioux Falls, South Dakota
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Elizabeth Yeu, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Avedro, Bausch + Lomb, BioTissue, Beaver Visitec, BlephEx, Bruder, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, LENSAE, Merck, Mynosys, Novartis, Ocular Science, Ocular Therapeutix, Ocusoft, Omeros, Oyster Point Pharma, Science Based Health, Shire, Sight Sciences, Sun Pharma, Surface, Thea, Tarsus, TopCon, TearLab, Visus Therapeutics, and Zeiss. Grant/Research Support: Alcon Vision, BioTissue, Ocular Science, TopCon, and TearLab. Stock/Shareholder: BlephEx, CorneaGen, Melt, Ocular Science, Oyster Point Pharma, and Tarsus.
John P. Berdahl, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Aerpio, Alcon, Allergan, Avedro, Aurea Medical, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Dakota Lions Eye Bank, Equinox, Expert Opinion, Glaukos, Gore, Imprimis, iRenix, Iacta Pharmaceuticals, Johnson & Johnson Vision, Kala Pharmaceuticals, Kedalion, MELT Pharmaceuticals, MicroOptx, New World Medical, Ocular Surgical Data, Ocular Therapeutix, Omega Ophthalmic, Orasis, Oyster Point, RxSight, Sight Sciences, Surface Inc., Tarsus, Tear Clear, Vertex Ventures, ViaLase, Vittamed, Vance Thompson Vision, and Visionary Ventures. Speaker’s Bureau: Alcon, Allergan, and Glaukos. Stock/Shareholder: Carl Zeiss Meditec, CorneaGen, Equinox, Expert Opinion, Ocular Surgical Data, Omega Ophthalmic, Surface Inc, and Vance Thompson Vision.
The Evolve and The Fundingsland Group planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Orasis Pharmaceuticals.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Andrew R. Harrison, MD
Kian Eftekhari, MD
Andrew G. Lee, MD
Wendy W. Lee, MD
Nicholas Robert Mahoney, MD
Amina Malik, MD
Prem S. Subramanian, MD, PhD
Jeremiah Tao, MD, FACS
KOL KNOCKOUT™: Oculoplastics Edition – Sculpting Sight For Patients With Thyroid Eye Disease - Round 3
1.00 creditAndrew R. Harrison, MD
Andrew G. Lee, MD
Wendy W. Lee, MD
Nicholas Robert Mahoney, MD
Blake K. Williamson, MD, MPH, MS
Brett Mueller, DO, PhD
Taj Nasser, MD
Julie Marie Schallhorn, MD, MS
Evan D. Schoenberg, MD
F. Beau Swann, MD, MS
Rahul S. Tonk, MD, MBA
William F. Wiley, MD
KOL Knockout™ - Cataract Edition: More than Best Corrected Visual Acuity: Meeting Patient Refractive Expectations - Round 2
1.50 creditsBlake K. Williamson, MD, MPH, MS
Brett Mueller, DO, PhD
Taj Nasser, MD
Evan D. Schoenberg, MD
